Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zhibao Technology Inc
NASDAQ:ZBAO
|
CN |
Maat Pharma SA
Intangible Assets
Maat Pharma SA
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Maat Pharma SA
PAR:MAAT
|
Intangible Assets
€1.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Intangible Assets
€22.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-14%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Intangible Assets
€4.2m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
39%
|
CAGR 10-Years
21%
|
|
|
Inventiva SA
PAR:IVA
|
Intangible Assets
€85k
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Intangible Assets
$22k
|
CAGR 3-Years
30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
|
|
Abivax SA
PAR:ABVX
|
Intangible Assets
€6.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Maat Pharma SA
Glance View
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
See Also
What is Maat Pharma SA's Intangible Assets?
Intangible Assets
1.8m
EUR
Based on the financial report for Dec 31, 2025, Maat Pharma SA's Intangible Assets amounts to 1.8m EUR.
What is Maat Pharma SA's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
20%
Over the last year, the Intangible Assets growth was 4%. The average annual Intangible Assets growth rates for Maat Pharma SA have been 15% over the past three years , 20% over the past five years .
